Golimumab for treating non-radiographic axial spondyloarthritis - guidance (TA497)

National Institute for Health and Care Excellence - NICE
Publication date:
10 January 2018


Evidence-based recommendations on golimumab (Simponi) for severe non-radiographic axial spondyloarthritis. This drug is for adults who have tried nonsteroidal anti-inflammatory drugs (NSAIDs), but they have not worked.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: December 2020